

MoH to price 1st lung cancer immunotherapy

The health ministry will set the price of AstraZeneca's lung cancer immunotherapy Imfinzi (durvalumab), the only immunotherapy to demonstrate overall survival in unresectable stage 3 cell lung cancer. The company's 30 drugs generated EGP 1.40 billion last year and it targets EGP 1.7 billion in 2019.